This invention is concerned with a novel polymorphic form of the compound 2-(R)-(1-(R)-(3,5-bis(trifluoromethyl)-phenyl)-ethoxy)-3-(S)-(4-fluoro)phe nyl-4-(3-(5-oxo-1H,4H-1,2,4-triazolo)methylmorpholine which is a tachykinin receptor antagonist useful in the treatment or prevention of disorders of the central nervous system, inflammatory diseases, pain or migraine, asthma, and emesis. The instant polymorphic form has advantages over the other known forms of 2-(R)-(1-(R)-(3,1-bis(trifluoro-methyl)-phenyl)ethoxy)-3-(S)-(4-fluoro)phe nyl-4-(3-(5-oxo-1H,4H-1,2,4-triazolo)methylmorpholine in terms of thermodynamic stability and suitability for inclusion in pharmaceutical formulations.

Esta invenção é concernida com um formulário polymorphic da novela do 2-(R)-(1-(R)-(3,5-bis(trifluoromethyl)-phenyl)-ethoxy)-3-(S)-(4-fluoro)phe composto nyl-4-(3-(5-oxo-1H, 4H-1, 2, 4-triazolo)methylmorpholine qual é um antagonista do receptor do tachykinin útil no tratamento ou a prevenção dos disorders do sistema nervoso central, as doenças inflammatory, a dor ou o migraine, o asthma, e o emesis. O formulário polymorphic instantâneo tem o excesso das vantagens os outros formulários sabidos de 2-(R)-(1-(R)-(3,1-bis(trifluoro-methyl)-phenyl)ethoxy)-3-(S)-(4-fluoro)phe nyl-4-(3-(5-oxo-1H, 4H-1, 2, 4-triazolo)methylmorpholine nos termos da estabilidade thermodynamic e suitability para o inclusion em formulations pharmaceutical.